Form 4: Beta Bionics Executive Acquires Shares and Options in Company
SEC Form 4 Filing
Mike Mensinger, Chief Product Officer of Beta Bionics, reports acquisition of common stock and stock options.
Summary
- Mike Mensinger, Chief Product Officer of Beta Bionics, filed a Form 4 detailing changes in beneficial ownership.
- On February 27, 2025, Mensinger acquired 35,000 shares of common stock through a restricted stock unit award and 52,000 shares via an employee stock option.
- The option has an exercise price of $19.91 and vests in 36 equal monthly installments from February 27, 2025, expiring on February 26, 2035.
- Following the reported transactions, Mensinger directly owns 94,019 shares of common stock and options for 52,000 shares.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard insider transaction. The acquisition of shares and options by an executive is generally a positive sign, but it's a routine event.
Positives
- The acquisition of shares and options by a key executive signals confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.
Stakeholder Impact
- The transactions may have a minor positive impact on shareholder sentiment due to the executive's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of earliest transaction, grant date of restricted stock units and stock options, and start of vesting period. |
| 02/26/2035 | Expiration date of the employee stock options. |
| 03/03/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.